RxDoctor Payments Data

Kenny Susanto, MD

Neurology · Tulsa, OKNPI 1255783270

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (53.7%), food and beverage and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 67.8% of it on its own, with 17 other manufacturers making up the rest.

$11,238in general payments, 2019–2025

Across 172 payments — averaging $65.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$8K
  • Boston Scientific$2K
  • Sunovion Pharmaceuticals Inc.$613
  • AbbVie$330
  • Pfizer$174
  • Greenwich Biosciences, Inc.$172
  • plus $605 from 12 others

What the payments were for

  • Travel & lodging$6,02954%
  • Food & beverage$5,13446%
  • Education$741%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,238 in reported general payments places this provider in the 70th percentile of 152 neurology providers in Oklahoma.

See all neurology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$147,022
Medicare patients
254
Services billed
9,850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GocovriAmantadine Hcl28$47,346
RytaryCarbidopa/Levodopa30$31,580
BotoxOnabotulinumtoxina12$19,670
Carbidopa-LevodopaCarbidopa/Levodopa272$9,475
Ajovy SyringeFremanezumab-Vfrm13$8,920
Emgality PenGalcanezumab-Gnlm12$8,058
Carbidopa-Levodopa ErCarbidopa/Levodopa121$5,988
AmantadineAmantadine Hcl96$3,885
OngentysOpicapone11$3,580
Carbidopa14$2,764
Pyridostigmine Bromide16$1,251
Primidone56$1,133
Topiramate27$786
Levetiracetam41$607
Memantine Hcl18$432

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$330$19,67012 claims
Upsher-smith Laboratories LLCTopiramate$13$78627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 152 neurology providers in Oklahoma.

Other neurology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →